CAJ | 학술논문

目的进一步验证青黄散治疗慢性粒细胞白血病(CML)的临床疗效.方法用单纯中药青黄散治疗CML86例,部分患者(28例)配合汤药(活血化瘀).结果 86例患者中,完全缓解62例(72.1%),部分缓解14例(16.3%),进步8例(9.3%),无效2例(2.3%),总有效率97.7%.该组病例服药1周自觉症状改善.肝大者44例,用药后39例较治疗前缩小或缩至正常;脾大者70例,治疗后69例较治疗前缩小,其中60例脾大完全消失,仅1例治疗前后无改变.脾开始缩小时间平均15.5 d,缩至最小平均62.9 d.白细胞数治疗后平均10.4 d开始下降,降至正常范围平均54.8 d.主要不良反应为消化道症状,其次是皮肤色素沉着、皮肤过度角化,从小剂量开始一般可以避免.结论青黄散可诱导CML缓解,并可改善临床症状,消除白血病细胞的浸润,对血红蛋白及血小板无显著影响.
목적 진일보험증청황산치료만성립세포백혈병(CML)적림상료효.방법 용단순중약청황산치료CML86례,부분환자(28례)배합탕약(활혈화어).결과 86례환자중,완전완해62례(72.1%),부분완해14례(16.3%),진보8례(9.3%),무효2례(2.3%),총유효솔97.7%.해조병례복약1주자각증상개선.간대자44례,용약후39례교치료전축소혹축지정상;비대자70례,치료후69례교치료전축소,기중60례비대완전소실,부1례치료전후무개변.비개시축소시간평균15.5 d,축지최소평균62.9 d.백세포수치료후평균10.4 d개시하강,강지정상범위평균54.8 d.주요불량반응위소화도증상,기차시피부색소침착、피부과도각화,종소제량개시일반가이피면.결론 청황산가유도CML완해,병가개선림상증상,소제백혈병세포적침윤,대혈홍단백급혈소판무현저영향.
Objective To verify the clinical effect of Qinghuang powder in chronic myelogenous leukemia(CML). Methods 86 CML patients treated with Qinghuang powder, in which 28 cases also partially received herbal medicine (activating blood circulation to dissipate blood stasis). Results 62 cases had complete remission (72.1%), 14 cases partial remission (16.3 %), advance 8 cases(9.3 %), inefficiency 2 cases (2.3 %), and the total efficiency was 97.7 %. The symptom were improved after a week when patients had taken medicines. 44 cases have hepatomegalia, among them 39 cases have diminished or became normal compared to untreated. 70 cases have splenoparectasis, among them 60 cases became normal, 9 cases diminished, and 1 case had no change after treatment. It took 15.5 days in average when spleen began to diminish, and took 62.9 days to become smallest. The WBC began to decrease at 10.4 day and took 54.8 days in average became normal. The major side effect was digestive tract symptom, followed by skin pigmentation and skin excessive cornification. It could be avoided by low dosage. Conclusion Qinghuang powder could not only induce CML to CR, but also improve the clinical symptom of CML and eliminate the infiltration of leukemia cells. It has little influence to Hb and Plt.